| Bioactivity | Tuvonralimab (PSB-205; QL1706) is a dual immune checkpoint blockade containing a mixture of anti-PD-1 IgG4 and anti-CTLA-4 IgG1 antibodies, Iparomlimab and Tuvonralimab[1]. |
| Invitro | Tuvonralimab 包含重链和轻链配对的突变 (HC 突变 K147D/F170C/V173C/C220G/R255K/D399R/K409E；轻链突变 S131K/Q160C/S162C/C214S)，但不用于产生双特异性抗体。最终的药物物质是两种单特异性 IgG 的混合物，即 Iparomlimab 和 Tuvonralimab。这两种抗体由同一细胞系产生，Tuvonralimab 内的突变确保了正确链的有效配对。Iparomlimab 不包含突变[1]。 |
| Name | Tuvonralimab |
| CAS | 2417649-44-4 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Ian Wilkinson, et al. Systematic analysis of the varied designs of 819 therapeutic antibodies and Fc fusion proteins assigned international nonproprietary names. MAbs. 2022 Jan-Dec;14(1):2123299. |